Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-BCMA antibody-drug conjugate CC-99712

An antibody-drug conjugate (ADC) consisting of a monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA, TNFRSF17), linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-BCMA ADC CC-99712, the antibody moiety targets and binds to the cell surface antigen BCMA expressed on certain cancer cells. Upon binding and internalization, the cytotoxic agent is released and kills the BCMA-expressing cancer cells through an as of yet unknown mechanism of action. BCMA, a receptor for a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma survival. It is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-BCMA ADC CC-99712
anti-BCMA antibody drug conjugate CC-99712
Code name:CC 99712
CC-99712
CC99712
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search